Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches (Q36723824)

15 August 2017

1 reference

title

Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches (English)

1 reference

Hormone Replacement Therapy

15 August 2017

1 reference

Gillian A Gray

3

0 references

David E Newby

series ordinal

2

object named as

David Newby

1 reference

15 August 2017

Helen Jeanes

1

1 reference

PubMed ID

17266463

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

279-288

1 reference

15 August 2017

3

1 reference

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Protective effects of estrogen on the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen deprivation, rather than age, is responsible for the poor lipid profile and carbohydrate metabolism in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Perspectives on the Women's Health Initiative trial of hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Mortality associated with hormone replacement therapy in younger and older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Modulatory influences on ageing of the vasculature in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

The metabolic basis for the effects of HRT on coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

In vitro effects of progesterone and progestins on vascular cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Clinical value of carotid intima-media thickness testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Mannheim intima-media thickness consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen receptor-alpha variants are associated with lipoprotein size distribution and particle levels in women: the Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Association of an estrogen receptor-alpha gene polymorphism with left ventricular mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen receptor-alpha thymidine and adenine repeat polymorphism and endothelial fibrinolytic regulation in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen receptor 2 and progesterone receptor gene polymorphisms and lipid levels in women with different hormonal status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Oestrogen and the cardiovascular system: the good, the bad and the puzzling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Mechanisms of estrogen action in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen receptor beta--a new dimension in estrogen mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Activation of estrogen receptor-alpha protects the in vivo rabbit heart from ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen receptors activate atrial natriuretic peptide in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen receptor-alpha mediates acute myocardial protection in females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Cardiovascular effects of raloxifene: the arterial and venous systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Women and ischemic heart disease: pathophysiologic implications from the Women's Ischemia Syndrome Evaluation (WISE) Study and future research steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Gender and heart failure: a population perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.279

21 January 2018

Identifiers

DOI

10.1517/14656566.8.3.279

1 reference

15 August 2017

1 reference

PubMed ID

17266463